表紙
市場調査レポート

全身性エリテマトーデス (SLE) :主要ヶ国の市場予測 (2016〜2026年)

Systemic Lupus Erythematosus Forecast in 8 Major Markets 2016-2026

発行 Black Swan Analysis 商品コード 353262
出版日 ページ情報 英文 48 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.75円で換算しております。
Back to Top
全身性エリテマトーデス (SLE) :主要ヶ国の市場予測 (2016〜2026年) Systemic Lupus Erythematosus Forecast in 8 Major Markets 2016-2026
出版日: 2016年03月01日 ページ情報: 英文 48 Pages
概要

全身性エリテマトーデス (SLE) は、核および細胞質抗原に対する自己抗体反応を特徴とする自己免疫疾患です。SLEは兆候と症状が広範にわたる全身性疾患であり、症状の再発と寛解を繰り返す慢性疾患です。SLEは皮膚、関節、腎臓、脳、身体の血液細胞および他の器官の機能および外観に影響を与えます。

当レポートでは、世界の主要9ヶ国 (米国、フランス、ドイツ、イタリア、スペイン、英国、ブラジル、および日本) における全身性エリテマトーデス (SLE) の発症状況について分析し、疾患の概要や現時点での有病者数、性別・年代別 (5歳区切り) の詳細状況、地域別・民族別傾向、リスク要因、疾患の診断と予後、主な症状や合併症、将来的な動向見通し (今後10年間分) といった情報を取りまとめてお届けいたします。

図表

イントロダクション

病因

危険因子と予防

疾患の診断

変異:地域/民族別

疾患予後と臨床経過

疾患に関連する主な合併症/特徴

患者数の定量化の方法

全身性エリテマトーデス (SLE) の最大の有病者数

SLE患者の特徴

  • SLEの発症タイプ
  • 神経精神病の兆候
  • SLEの補体値
  • SLEの抗体
  • SLE関連の関節痛
  • 心肺の関わり
  • 血液疾患
  • 皮膚病変

ループス腎炎の特徴

略語

関連出版

患者ベースのオンラインデータベース

患者ベースの製品

価格のオンラインデータ・プラットフォーム

参考文献

付録

目次
Product Code: SLES0010216

image1

Systemic Lupus Erythematosus (SLE) is an autoimmune disease, characterised by an autoantibody response to nuclear and cytoplasmic antigens. It is a systemic disease, with a large spectrum of signs and symptoms. It is a chronic condition that follows a relapsing and remitting course of its associated manifestations. It can affect the functions and appearance of skin, joints, kidneys, brain, the body's blood cells and other organs.

This report provides the current prevalent population for SLE across 8 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil and Japan) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of SLE have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for SLE include:

  • Osteoporosis
  • Infections
  • Skin lesions & conditions
  • Arthritis
  • Anaemia
  • Raynaud's phenomenon
  • Serositis
  • Lupus Nephritis

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

  • Able to quantify patient populations in global SLE's market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of SLE and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on SLE's prevalent population.
  • Identify sub-populations within SLE which require treatment.
  • Gain an understanding of the specific markets that have the largest number of SLE patients.

Coverage

US, UK, FR, DE, IT, ES, JP, BR

image2

Table of Contents

List of Tables and Figures

Introduction

Cause of the Disease

Risk Factors & Prevention

Diagnosis of the Disease

Variation by Geography/Ethnicity

Disease Prognosis & Clinical Course

Key Co-morbid Conditions/ Features Associated with the Disease

Methodology for Quantification of Patient Numbers

Top-Line Prevalence for Systematic Lupus Erythematosus

Features of SLE Patients

  • SLE Onset Type
  • Neuropsychiatric Manifestations
  • Complement Levels in SLE
  • Anti-bodies in SLE
  • Associated Joint Pain of SLE
  • Cardio-Pulmonary Involvement
  • Haematological Disorders
  • Cutaneous Involvements

Features of Lupus Nephritis Patients

Abbreviations used in the Report

Other Black Swan Analysis Publications

Black Swan Analysis Online Patient-Based Databases

Patient-Based Offering

Online Pricing Data and Platforms

References

Appendix

List of Tables & Figures

  • ACR Classification Criteria for SLE
  • WHO morphologic classification of lupus nephritis
  • Prevalence of SLE, total (000s)
  • Prevalence of SLE, males (000s)
  • Prevalence of SLE, females (000s)
  • Onset type of SLE in patients, total (000s)
  • Neuropsychiatric manifestations in SLE patients, total (000s)
  • Level of cognitive dysfunction in SLE patients, total (000s)
  • Prevalence of hypocomplementemia in SLE patients, total (000s)
  • SLE patients with low levels of complement, total (000s)
  • SLE patients with anti-nuclear antibodies, total (000s)
  • SLE patients with anti-DNA antibodies, total (000s)
  • SLE patients with anti-Ro (SSA) antibodies, total (000s)
  • SLE patients with anti-La (SSB) antibodies, total (000s)
  • Prevalence of SLE patients with arthritis, total (000s)
  • Prevalence of SLE patients with Jaccoud's arthritis, total (000s)
  • Prevalence of SLE patients with osteonecrosis, total (000s)
  • Carotid plaque burden in SLE patients, total (000s)
  • Prevalence of serositis, total (000s)
  • Serositis associated conditions in SLE patients, total (000s)
  • Prevalence of haematological disorders, total (000s)
  • Types of haematological disorders in SLE patients, total (000s)
  • Prevalence of cutaneous involvement in SLE patients, total (000s)
  • Prevalence of specific dermatological conditions, total (000s)
  • Prevalence of lupus nephritis, total (000s)
  • Prevalence of renal replacement in lupus nephritis patients, total (000s)
  • Severity of lupus nephritis by WHO class, total (000s)
  • Abbreviations and Acronyms used in the Report
  • USA Prevalence of SLE by 5-yr age cohort, males (000s)
  • USA Prevalence of SLE by 5-yr age cohort, females (000s)
  • France Prevalence of SLE by 5-yr age cohort, males (000s)
  • France Prevalence of SLE by 5-yr age cohort, females (000s)
  • Germany Prevalence of SLE by 5-yr age cohort, males (000s)
  • Germany Prevalence of SLE by 5-yr age cohort, females (000s)
  • Italy Prevalence of SLE by 5-yr age cohort, males (000s)
  • Italy Prevalence of SLE by 5-yr age cohort, females (000s)
  • Spain Prevalence of SLE by 5-yr age cohort, males (000s)
  • Spain Prevalence of SLE by 5-yr age cohort, females (000s)
  • United Kingdom Prevalence of SLE by 5-yr age cohort, males (000s)
  • United Kingdom Prevalence of SLE by 5-yr age cohort, females (000s)
  • Brazil Prevalence of SLE by 5-yr age cohort, males (000s)
  • Brazil Prevalence of SLE by 5-yr age cohort, females (000s)
  • Japan Prevalence of SLE by 5-yr age cohort, males (000s)
  • Japan Prevalence of SLE by 5-yr age cohort, females (000s)
Back to Top